Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma

Cancer Immunology Immunotherapy

Volumn 48, Issue 12, 2000, Pages 691-702

  Tordsson, Jesper Max ^a   Ohlsson, Lennart Göran ^a   Abrahmsén, Lars Bertil ^b   Karlström, Pia Jasmine ^a   Lando, Peter Anders ^a   Brodin, Thomas Nils ^a  

^a Active Biotech Research AB   (Sweden)

^b PFIZER INC   (United States)

Author keywords

HMW MAA; Monoclonal antibody; Phage display; Primate; Superantigen

Indexed keywords

EPITOPE; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; STAPHYLOCOCCUS ENTEROTOXIN; SUPERANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOPHAGE; BINDING AFFINITY; CELL SURFACE; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIMATE; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0034018019     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050018     Document Type: Article

References (51)

1. Abrahmsen L, Dohlsten M, Segren S, Bjork P, Jonsson E, Kalland T (1995) Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J 14:2978
2. Anderson CM, Buzaid AC, Legha SS (1995) Systemic treatments for advanced cutaneous melanoma. Oncology (Huntingt) 9:1149
3. Arndt KM, Muller KM, Pluckthun A (1998) Factors influencing the dimer to monomer transition of an antibody single- chain Fv fragment. Biochemistry 37:12918
4. Bender H, Grapow M, Schomburg A, Reinhold U, Biersack HJ (1997) Effects of diagnostic application of monoclonal antibody on survival in melanoma patients. Hybridoma 16:65
5. Brodin TN, Persson R, Soegaard M, Ohlsson L, D Argy R, Olsson J, Molander A, Antonsson P, Gunnarsson PO, Kalland T (1998) Man-made superantigens: tumor-selective agents for T-cell-based therapy. Adv Drug Deliv Rev 31:131
6. Bumol TF, Walker LE, Reisfeld RA (1984) Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans. J Biol Chem 259:12733
7. Carson DA, Freimark BD (1986) Human lymphocyte hybridomas and monoclonal antibodies. Adv Immunol 38:275- 311:275
8. Clark RK, Trainer DL, Bailey DS, Greig RG (1989) Immunohistochemical analysis of antiserum from rhesus monkeys immunized with human colon carcinoma. Cancer Res 49:3656
9. Conforti AM, Ollila DW, Kelley MC, Gammon G, Morton DL (1997) Update on active specific immunotherapy with melanoma vaccines. J Surg Oncol 66:55
10. Del Vecchio S, Reynolds JC, Blaśberg RG, Neumann RD, Carrasquillo JA, Hellstrom I, Larson SM (1988) Measurement of local Mr 97,000 and 250,000 protein antigen concentration in sections of human melanoma tumor using in vitro quantitative autoradiography. Cancer Res 48:5475
11. Desai SA, Wang X, Noronha EJ, Kageshita T, Ferrone S (1998) Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library. Cancer Res 58:2417
12. Dohlsten M, Abrahmsen L, Bjork P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NR, Forberg C, Lind P (1994) Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci USA 91:8945
13. Fraker PJ, Speck JC, Jr. (1978) Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 80:849
14. Fujimori K, Covell DG, Fletcher JE, Weinstein JN (1989) Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors. Cancer Res 49:5656
15. Garin-Chesa P, Beresford HR, Carrato-Mena A, Oettgen HF, Old LJ, Melamed MR, Rettig WJ (1989) Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems. Am J Pathol 134:295
16. Giacomini P, Veglia F, Cordiali Fei P, Rehle T, Natali PG, Ferrone S (1984) Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma. Cancer Res 44:1281
17. Hamby CV, Liao SK, Kanamaru T, Ferrone S (1987) Immunogenicity of human melanoma-associated antigens defined by murine monoclonal antibodies in allogeneic and xenogeneic hosts. Cancer Res 47:5284
18. Harper JR, Reisfeld RA (1983) Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan. J Natl Cancer Inst 71:259
19. Hersey P (1985) Review of melanoma antigens recognized by monoclonal antibodies (MAbs). Their functional significance and applications in diagnosis and treatment of melanoma. Pathology 17:346
20. Holzer U, Bethge W, Krull F, Ihle J, Handgretinger R, Reisfeld RA, Dohlsten M, Kalland T, Niethammer D, Dannecker GE (1995) Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells. Cancer Immunol Immunother 41:129
21. Hoogenboom HR, de Bruine AP, Hufton SE, Hoet RM, Arends JW, Roovers RC (1998) Antibody phage display technology and its applications. Immunotechnology 4:1
22. Irie RF, DeNunzio FD (1993) Immunotherapy of melanoma: current status and prospects for the future. J Dermatol 20:65
23. Kageshita T, Kuriya N, Ono T, Horikoshi T, Takahashi M, Wong GY, Ferrone S (1993) Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. Cancer Res 53:2830
24. Khazaeli MB, Conry RM, LoBuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother 15:42
25. Kruif J de, Terstappen L, Boel E, Logtenberg T (1995) Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. Proc Natl Acad Sci USA 92:3938
26. Krull F, Holzer U, Ihle J, Bethge W, Fierlbeck G, Kalland T, Dohlsten M, Niethammer D, Dannecker GE (1997) Superantigen-induced lysis of melanoma cells. Melanoma Res 7:214
27. Lando PA, Dohlsten M, Ohlsson L, Kalland T (1995) Tumor-reactive superantigens suppress tumor growth in humanized SCID mice. Int J Cancer 62:466
28. Larson SM, Carrasquillo JA, McGuffin RW, Krohn KA, Ferens JM, Hill LD, Beaumier PL, Reynolds JC, Hellstrom KE, Hellstrom I (1985) Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience. Radiology 155:487
29. Lewis AP, Barber KA, Cooper HJ, Sims MJ, Worden J, Crowe JS (1993) Cloning and sequence analysis of kappa and gamma cynomolgus monkey immunoglobulin cDNAs. Dev Comp Immunol 17:549
30. Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM (1996) Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci USA 93:8618
31. Logdberg L, Kaplan E, Drelich M, Harfeldt E, Gunn H, Ehrlich P, Dottavio D, Lake P, Ostberg L (1994) Primate antibodies to components of the human immune system. J Med Primatol 23:285
32. Mittelman A, Wang X, Matsumoto K, Ferrone S (1995) Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma 14:175
33. Newman R, Alberts J, Anderson D, Carner K, Heard C, Norton F, Raab R, Reff M, Shuey S, Hanna N (1992) "Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4. Biotechnology 10:1455
34. Oldham RK, Foon KA, Morgan AC, Woodhouse CS, Schroff RW, Abrams PG, Fer M, Schoenberger CS, Farrell M, Kimball E (1984) Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. J Clin Oncol 2:1235
35. Pietersz GA, Krauer K (1994) Antibody-targeted drugs for the therapy of cancer. J Drug Target 2:183
36. Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ, Reisfeld RA (1996) Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc Natl Acad Sci USA 93:9710
37. Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323
38. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma (see comments). Nat Med 4:321
39. Saga T, Neumann RD, Heya T, Sato J, Kinuya S, Le N, Paik CH, Weinstein JN (1995) Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA 92:8999
40. Siccardi AG, Buraggi GL, Natali PG, Scassellati GA, Viale G, Ferrone S (1990) European multicentre study on melanoma immunoscintigraphy by means of 99mTc-labelled monoclonal antibody fragments. The European Multicentre Study Group. Eur J Nucl Med 16:317
41. Sogaard M, Hansson J, Litton MJ, Ohlsson L, Rosendahl A, Lando PA, Antonsson P, Kalland T, Dohlsten M (1996) Antibody-targeted superantigens in cancer immunotherapy. Immunotechnology 2:151
42. Stuhlmiller GM, Darrow TL, Haupt DM, Seigler HF (1987) Immune response of chimpanzee to purified melanoma 250 kilodalton tumor-associated antigen. Cancer Immunol Immunother 25:193
43. Stuhlmiller GM, Mohanakumar T, Metzgar RS, Seigler HF (1976) The use of non-human primates for production of antisera to human tumor-associated antigens. J Immunol Methods 12:267
44. Svensson LA, Schad EM, Sundstrom M, Antonsson P, Kalland T, Dohlsten M (1997) Staphylococcal enterotoxins A, D, and E: structure and function, including mechanism of T-cell superantigenicity: In: Leung DYM, Huber BT, Schlievert PM (eds). Superantigens. Molecular biology, immunology and relevance to human disease. Dekker, New York, NY, p 199
45. Takahashi T, Irie RF, Morton DL, Hoon DS (1997) Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patients. Cell Immunol 178:162
46. Toes RE, Offringa R, Feltkamp MC, Visseren MJ, Schoenberger SP, Melief CJ, Kast WM (1994) Tumor rejection antigens and tumor specific cytotoxic T lymphocytes. Behring Inst Mitt 94:72
47. Tordsson J, Abrahmsen L, Kalland T, Ljung C, Ingvar C, Brodin T (1997) Efficient selection of scFv antibody phage by adsorption to in situ expressed antigens in tissue sections. J Immunol Methods 210:11
48. Truneh A, Frescatore RL, Thiem P, Leary JJ, Rosenberg M, Hanna N, Sweet R, Bugelski PJ (1990) Humoral response of cynomolgus macaques to human soluble CD4: antibody reactivity restricted to xeno-human determinants. Cell Immunol 131:98
49. Wallgren A, Festin R, Gidlof C, Dohlsten M, Kalland T, Totterman TH (1993) Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells. Blood 82:1230
50. Woodhouse CS, Bordonaro JP, Beaumier PL, Morgan ACJ (1990) Second generation monoclonal antibodies to a human melanoma-associated proteoglycan: In: Ferrone S (ed) Human melanoma. Springer, Berlin, Heidelberg New York, p 151
51. Ziai MR, Imberti L, Nicotra MR, Badaracco G, Segatto O, Natali PG, Ferrone S (1987) Analysis with monoclonal antibodies of the molecular and cellular heterogeneity of human high molecular weight melanoma associated antigen. Cancer Res 47:2474